---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-22-000048"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:00:09.716418+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q3 revenue $13.5M, cuts FY guidance to $51.5-52.5M; extends credit line to 2027

## Summary
- Q3 revenue $13.5M (+2% YoY, +7% constant currency); US $8.4M (+22%), intl $5.1M (-20%).
- Net loss $14.2M ($0.38/sh) vs $10.2M ($0.28) in Q3 2021; gross margin 75% vs 73%.
- FY2022 revenue guidance cut to $51.5-52.5M from $55-60M; opex guidance lowered to $98-100M.
- Extended loan with CIBC: maturity to Oct 2027, new $20M tranche, 24-month interest-only period.
- Japan MHLW agreed to approve Zephyr Valves; AeriSeal data may expand treatable patient pool.

## SEC filing metadata
- accession: 0001127537-22-000048
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/lung-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-22-000048
- JSON: https://secwatch.observer/filing/0001127537-22-000048.json
- Plain text: https://secwatch.observer/filing/0001127537-22-000048.txt

## Key facts
- Earnings Releases
  Pulmonx Corp reported third quarter ended September 30, 2022 results: revenue 13.5 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: 13.5 million
  - Result: reported results
  source text: invasive treatments for lung disease, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights • Achieved worldwide revenue of $13.5 million in the third quarter of 2022, a 2% increase over the same period last year and an increase of 7% on a constant currency basis, driven by U.S. revenue of $8.4 million representing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm
- Earnings Releases
  Pulmonx Corp reported full year 2022 results: revenue 51.5 million to 52.5 million. Guidance lowered.
  - Period: full year 2022
  - Revenue: 51.5 million to 52.5 million
  - Guidance: lowered
  - Result: guidance update
  source text: Pulmonx is updating its full year 2022 revenue guidance to be in the range of $51.5 million to $52.5 million, as compared to previously communicated guidance of $55 million to $60 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm
- Material Agreements
  Pulmonx Corp amended Third Amendment to Amended and Restated Loan and Security Agreement with Canadian Imperial Bank of Commerce valued at $20,000,000 (effective 2022-10-31).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Canadian Imperial Bank of Commerce
  - Value: $20,000,000
  - Effective: 2022-10-31
  source text: On October 31, 2022, the Company executed a Third Amendment to Amended and Restated Loan and Security Agreement (the “Third Amendment”) with Canadian Imperial Bank of Commerce (“CIBC”), which amended certain provisions of the Company’s existing Amended and Restated Loan and Security Agreement, dated as of March 29, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.